Currently, the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), American Association of Clinical Endocrinologists (AACE), and American College of Endocrinology (ACE) recommend GLP-1RAs to be used as adjunct medications when adequate glucose control is not achieved with lifestyle interventions (including weight reduction) and a non-insulin oral drug [39,40,41]. The gene discussed is INS; the disease is diabetes mellitus.